NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares

$38.27

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

NewAmsterdam Pharma Company (NAMS) is set to report its earnings on November 17, 2025, with analysts closely watching the company's ability to maintain its market cap of approximately $4.29 billion amidst a challenging pharmaceutical landscape. Despite the absence of recent news, the focus will be on whether NAMS can meet the revenue estimate of $1.87 million, as the company has been navigating a period of strategic recalibration. The EPS estimate stands at $0.00, aligning with the whisper number, suggesting that expectations are tempered, likely due to ongoing investments in research and development that could position the company for future growth. Investors will be keen to see if NAMS can leverage its current market position to drive innovation and long-term profitability, even as immediate earnings remain flat.

Updated On 11/21/2025

About NewAmsterdam Pharma Company N.V. Ordinary Shares

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1936258
Address
GOOIMEER 2-35, NAARDEN, NL
Valuation
Market Cap
$1.79B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.37
Performance
EPS
$-2.56
Dividend Yield
—
Profit Margin
0.00%
ROE
-46.20%
Technicals
50D MA
$20.12
200D MA
$19.96
52W High
$27.29
52W Low
$14.06
Fundamentals
Shares Outstanding
110M
Target Price
$47.06
Beta
-0.00

NAMS EPS Estimates vs Actual

● Estimated
● Actual

NAMS News & Sentiment

Nov 05, 2025 • Zacks Commentary NEUTRAL
NewAmsterdam Pharma Company N.V. ( NAMS ) Reports Q3 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -7.89% and -91.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 04, 2025 • Zacks Commentary NEUTRAL
Madrigal ( MDGL ) Reports Q3 Loss, Tops Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of -156.57% and +15.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 29, 2025 • Zacks Commentary NEUTRAL
NewAmsterdam Pharma Company N.V. ( NAMS ) Expected to Beat Earnings Estimates: Should You Buy?
NewAmsterdam Pharma Company N.V. (NAMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 07, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NewAmsterdam Pharma Company N.V. ( NAMS ) Soars 5.9%: Is Further Upside Left in the Stock?
NewAmsterdam Pharma Company N.V. (NAMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Aug 18, 2025 • Benzinga NEUTRAL
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib - NewAmsterdam Pharma Co ( NASDAQ:NAMSW ) , NewAmsterdam Pharma Co ( NASDAQ:NAMS )
-- Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia ( heterozygous familial and non-familial ) or mixed dyslipidemia --
Aug 07, 2025 • Motley Fool NEUTRAL
NewAmsterdam ( NAMS ) Q2 Revenue Jumps 49%
NewAmsterdam Pharma ( NASDAQ:NAMS ) , a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, delivered its Q2 2025 earnings report on August 6, 2025. The most important news from the release was GAAP revenue of $19.1 million, a significant ...
Sentiment Snapshot

Average Sentiment Score:

0.115
50 articles with scored sentiment

Overall Sentiment:

Neutral

NAMS Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.29 Surprise
  • Reported EPS: $-0.15
  • Estimate: $-0.44
  • Whisper: —
  • Surprise %: 65.9%
May 08, 2025
Mar 31, 2025 (Pre market)
0.14 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.44
  • Whisper: —
  • Surprise %: 31.8%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.93
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: 3.1%
Nov 06, 2024
Sep 30, 2024 (Pre market)
0.29 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.45
  • Whisper: —
  • Surprise %: 64.4%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.14 Surprise
  • Reported EPS: $-0.38
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: 26.9%
May 08, 2024
Mar 31, 2024 (Post market)
-0.51 Surprise
  • Reported EPS: $-0.99
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: -106.2%
Feb 28, 2024
Dec 31, 2023 (Post market)
0.01 Surprise
  • Reported EPS: $-0.54
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: 1.8%
Nov 13, 2023
Sep 30, 2023 (Pre market)
0.2 Surprise
  • Reported EPS: $-0.56
  • Estimate: $-0.76
  • Whisper: —
  • Surprise %: 25.8%
Aug 07, 2023
Jun 30, 2023 (Pre market)
-0.59 Surprise
  • Reported EPS: $-1.01
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: -140.5%

Financials